Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse
Clinical trial NCT04656951 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04656951
- Sponsor
- University of Cologne
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-01
- Primary completion
- 2025-03-15
- Enrollment
- 67
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.